Chronic Myeloid Leukemia

>

Latest News

Based on findings from the phase 1/2 BCHILD trial, the FDA approved bosutinib for pediatric chronic myelogenous leukemia.
FDA Approves Bosutinib for Pediatric Chronic Myelogenous Leukemia

September 27th 2023

Based on findings from the phase 1/2 BCHILD trial, the FDA approved bosutinib for pediatric chronic myelogenous leukemia.

Asciminib may be more tolerable than bosutinib in the treatment of those with chronic myeloid leukemia, according to Michael Deininger, MD.
Treatment Goals and Disease Risks May Inform Treatment Selection in CML

September 10th 2023

A major molecular response at 3 months appears to increase the probability of overall survival in patients treated with ponatinib for chronic-phase chronic myeloid leukemia in the phase 2 PACE trial.
Molecular Responses with Ponatinib Correlate with PFS/OS Outcomes in CML

September 8th 2023

Asciminib does not appear to interfere with the general life activities of patients with resistant/intolerant chronic phase chronic myeloid leukemia in the phase 3 ASCEMBL trial.
Asciminib May Improve HRQOL Vs Bosutinib in Resistant/Intolerant CML-CP

May 23rd 2023

Recap: Moffitt and Mayo Face-Off in CML Treatment Updates From ASH
Recap: Moffitt and Mayo Face-Off in CML Treatment Updates From ASH

April 5th 2023

Video Series
Video Interviews
Podcasts

More News